Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling

Chen, S., Zhou, M. L., Sun, J., Guo, A. W., Fernando, R. L., Chen, Y., Peng, P., Zhao, G., & Deng, Y. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107668 · Cited by 72

The role of glia in the physiology and pharmacology of glucagon‐like peptide‐1: implications for obesity, diabetes, neurodegeneration and glaucoma

Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 72

Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury

Greig, N. H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., Chiang, Y. H., Hoffer, B. J., Miller, J. P., Lahiri, D. K., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.011 · Cited by 71

Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease

Salles, G. N., Calió, M. L., Hölscher, C., Pacheco-Soares, C., Porcionatto, M., & Lobo, A. O. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107813 · Cited by 71

Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease

Fang, X., Zhou, X., Miao, Y., Han, Y., Wei, J., & Chen, T. (2020) · AMB Express · doi:10.1186/s13568-020-01014-6 · Cited by 70

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability

Ito, H., Nishio, S., & Abe, M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54679 · Cited by 70

Headache attributed to idiopathic intracranial hypertension and persistent post‐idiopathic intracranial hypertension headache: A narrative review

Mollan, S. P., Grech, O., & Sinclair, A. J. (2021) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14125 · Cited by 70

Amyloid-β Peptide Nitrotyrosination Stabilizes Oligomers and Enhances NMDAR-Mediated Toxicity

Guivernau, B., Bonet, J., Valls-Comamala, V., Bosch-Morató, M., Godoy, J. A., Inestrosa, N. C., Perálvarez-Marín, A., Fernández-Busquets, X., Andreu, D., Oliva, B., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1081-16.2016 · Cited by 69

Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

Chen, S., Yu, S., Li, Y., Lecca, D., Glotfelty, E. J., Kim, H. K., Choi, H., Hoffer, B. J., Greig, N. H., Kim, D. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28449-z · Cited by 68

Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats

Eakin, K. C., Li, Y., Chiang, Y. H., Hoffer, B. J., Rosenheim, H. M., Greig, N. H., & Miller, J. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082016 · Cited by 67

GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling

Wang, Y., Chen, S., Zheng, X., Chen, S., Yao, W., & Gao, X. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.048 · Cited by 67

The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease

Maskery, M. P., Goulding, E. M., Gengler, S., Melchiorsen, J. U., ROSENKILDE, M. M., & Hölscher, C. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317520953041 · Cited by 67

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice

Bhat, V. K., Kerr, B. D., Vasu, S., Flatt, P. R., & Gault, V. A. (2013) · Diabetologia · doi:10.1007/s00125-013-2892-2 · Cited by 66

Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway

Paris, D., Town, T., Mori, T., Parker, T. A., Humphrey, J., & MULLAN, M. J. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00111-6 · Cited by 66

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

Hansen, H. H., Fabricius, K., Barkholt, P., Wismann, P., Schlumberger, C., Jelsing, J., Terwel, D., Termont, A., Pyke, C., Knudsen, L. B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158205 · Cited by 65

Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease

Bomba, M., Granzotto, A., Castelli, V., ONOFRJ, M. C., Lattanzio, R., Cimini, A., & Sensi, S. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-190237 · Cited by 65

GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis

Malhotra, K., Katsanos, A. H., Lambadiari, V., Goyal, N., Palaiodimou, L., Kosmidou, M., Krogias, C., Alexandrov, A. V., & Tsivgoulis, G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09813-4 · Cited by 65

AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons

Soutar, M. P. M., Kempthorne, L., Miyakawa, S., Annuario, E., Melandri, D., Harley, J., O’Sullivan, G. A., Wray, S., Hancock, D. C., Cookson, M. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26949-6 · Cited by 65

Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer’s Disease

Wiciński, M., Wódkiewicz, E., Słupski, M., Walczak, M., Socha, M. W., Malinowski, B., & Pawlak-Osińska, K. (2018) · BioMed Research International · doi:10.1155/2018/6091014 · Cited by 64

Vildagliptin: a new oral treatment for type 2 diabetes mellitus

Mathieu, C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3005 · Cited by 63

Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease

Glotfelty, E. J., Olson, L., Karlsson, T. E., Li, Y., & Greig, N. H. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764534 · Cited by 63

The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01

Lv, M., Xue, G., Cheng, H.-F., Meng, P., Lian, X., Hölscher, C., & Li, D. (2021) · Brain and Behavior · doi:10.1002/brb3.2231 · Cited by 63

Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis

Dutta, D., Surana, V., Singla, R., Aggarwal, S., & Sharma, M. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_423_21 · Cited by 62

Neuroprotective Mechanisms of Glucagon‐like Peptide‐1‐based Therapies in Ischaemic Stroke: A Systematic Review based on Pre‐Clinical Studies

Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61

GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-κB pathway in neuropathic pain mice

Zhang, L.-Q., Zhang, W., Li, T., Yang, T., Yuan, X., Zhou, Y., Zou, Q., Yang, H., Gao, F., Tian, Y., et al. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107463 · Cited by 61

Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes

Zhang, M., Wu, Y., Gao, R., Chen, X., Chen, R., & Zhou, C. Y. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111529 · Cited by 61

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus

Kim, S., Yoo, J.-H., Lee, W. J., & Park, C. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.5.339 · Cited by 60

Fisetin Prevents HT22 Cells From High Glucose-Induced Neurotoxicity via PI3K/Akt/CREB Signaling Pathway

Zhang, S., Xue, R., Geng, Y., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00241 · Cited by 60

Blast traumatic brain injury–induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon‐like peptide‐1 receptor agonist, exendin‐4

Tweedie, D., Rachmany, L., Rubovitch, V., Li, Y., Holloway, H. W., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Hoffer, B. J., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.489 · Cited by 59

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease

Chen, Y., Zhang, J., Zhang, B., & Gong, C. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150813142423 · Cited by 59

Dipeptidyl peptidase-4 inhibition by Pterocarpus marsupium and Eugenia jambolana ameliorates streptozotocin induced Alzheimer's disease

Kosaraju, J., Madhunapantula, S. V., Chinni, S., Khatwal, R. B., Dubala, A., Nataraj, S. K. M., & Basavan, D. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.03.026 · Cited by 59

Long-acting preparations of exenatide

Yuan, W., Cai, Y., Wei, L. L., Ma, L., Huang, X., Tao, A., & Liu, Z. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46970 · Cited by 57

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH

Li, Q.-X., Gao, H., Guo, Y.-X., Wang, B.-Y., Hua, R.-X., Gao, L., Shang, H.-W., Lu, X., & Xu, J.-D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721198 · Cited by 56

Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest

Wiberg, S. C., Hassager, C., Schmidt, H., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.024088 · Cited by 55

Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors

Yuliantie, E., Darbalaei, S., Dai, A., Zhao, P., Yang, D., Sexton, P. M., Wang, M., & Wootten, D. L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114001 · Cited by 55

Diabetic Patients With Traumatic Brain Injury: Insulin Deficiency Is Associated With Increased Mortality

Ley, E. J., Srour, M. K., Clond, M. A., Barnajian, M., Tillou, A., Mirocha, J., & Salim, A. (2011) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3182146d66 · Cited by 55

Small Molecules As Central Nervous System Therapeutics: Old challenges, New directions, and a Philosophic Divide

Banks, W. A., & Greig, N. H. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0436 · Cited by 55

Emerging themes in idiopathic intracranial hypertension

Grech, O., Mollan, S. P., Wakerley, B. R., Alimajstorovic, Z., Lavery, G. G., & Sinclair, A. J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10090-4 · Cited by 55

Insulin resistance is associated with poor functional outcome after acute ischemic stroke in non-diabetic patients

Chang, Y., Kim, C. K., Kim, M., Seo, W., & Oh, K. (2021) · Scientific Reports · doi:10.1038/s41598-020-80315-z · Cited by 54

Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease

Cummings, J. L., Ortiz, A. A., Castellino, J., & Kinney, J. W. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15619 · Cited by 54

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

Ayoub, B. M., Mowaka, S., Safar, M. M., Ashoush, N., Arafa, M. G., Michel, H. E., Tadros, M. M., Elmazar, M. M., & Mousa, S. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-27395-0 · Cited by 54

Neuroinflammation in the Cerebellum and Brainstem in Friedreich Ataxia: An [ 18F ]‐ FEMPA PET Study

Khan, W., Corben, L. A., Bilal, H., Vivash, L. E., Delatycki, M. B., Egan, G. F., & Harding, I. H. (2021) · Movement Disorders · doi:10.1002/mds.28825 · Cited by 54

Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1

Chen, T., Tian, P., Huang, Z., Zhao, X., Wang, H., Xia, C., Wang, L., & Wei, H. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9155-6 · Cited by 52

Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process

Fu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 52

A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson's Disease

Hogg, E., Wu, T., Bresee, C., Wertheimer, J., Malatt, C., Tan, E., Pomeroy, H., Nuno, M., Wyse, R., & Tagliati, M. (2022) · doi:10.2139/ssrn.4212371 · Cited by 52

Glucagon‐like peptide‐1 protects synaptic and learning functions from neuroinflammation in rodents

Iwai, T., Sawabe, T., Tanimitsu, K., Suzuki, M., Sasaki‐Hamada, S., & Oka, J. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23335 · Cited by 51

Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration

Rachmany, L., Tweedie, D., Rubovitch, V., Li, Y., Holloway, H. W., Kim, D. S., Ratliff, W. A., Saykally, J. N., Citron, B. A., Hoffer, B. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-03792-9 · Cited by 49

Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury

Glotfelty, E. J., Delgado, T., Tovar‐y‐Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 48

Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury

Bader, M., Li, Y., Tweedie, D., Shlobin, N. A., Bernstein, A., Rubovitch, V., Tovar‐y‐Romo, L. B., DiMarchi, R. D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00356 · Cited by 48

The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration

Li, Y., Glotfelty, E. J., Karlsson, T. E., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47

Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats

Cai, H.-Y., Wang, Z., Hölscher, C., Li, Y., Zhang, J., Sun, P., Li, J., Yang, W., Wu, M., & Qi, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.10.033 · Cited by 46

Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats

Katsurada, K., Nakata, M., Saito, T., Zhang, B., Maejima, Y., Nandi, S. S., Sharma, N. M., Patel, K. P., Kario, K., & Yada, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-49364-x · Cited by 46

Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience

Foltynie, T., & Athauda, D. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 46

The Parkinson's disease gene PINK1 activates Akt via PINK1 kinase-dependent regulation of the phospholipid PI(3,4,5)P3

Furlong, R. M., Lindsay, A. J., Anderson, K. E., Hawkins, P. T., Sullivan, A. M., & O’Neill, C. (2019) · Journal of Cell Science · doi:10.1242/jcs.233221 · Cited by 46

Diabetes, Glycated Hemoglobin ( HbA1c) , and Neuroaxonal Damage in Parkinson's Disease ( MARK‐PD Study )

Uyar, M., Lezius, S., Buhmann, C., Pötter‐Nerger, M., Schulz, R. J., Meier, S., Gerloff, C. P., Kühle, J., & Choe, C. (2022) · Movement Disorders · doi:10.1002/mds.29009 · Cited by 46

Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis

Gharagozloo, M., Smith, M. D., Sotirchos, E. S., Jin, J., Meyers, K. R., Taylor, M., Garton, T. P., Bannon, R. N., Lord, H., Dawson, T. M., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01088-5 · Cited by 45

Glucagon action in the brain

Abraham, M. A., & Lam, T. K. T. (2016) · Diabetologia · doi:10.1007/s00125-016-3950-3 · Cited by 44

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential

Pathak, N. M., Pathak, V., Gault, V. A., McClean, S., Irwin, N., & Flatt, P. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.021 · Cited by 44

Involvement of P53 and Bax/Bad triggering apoptosis in thioacetamide-induced hepatic epithelial cells.

Chen, L., Hsu, C.-Y., & Weng, C. (2006) · Europe PMC (PubMed Central) · doi:10.3748/wjg.v12.i32.5175 · Cited by 44

Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury

Tamargo, I. A., Bader, M., Li, Y., Yu, S., Wang, Y., Talbot, K., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.005 · Cited by 43

Protection against stroke with glucagon‐like peptide 1 receptor agonists: a systematic review and meta‐analysis

Barkas, F., Elisaf, M., & Milionis, H. J. (2019) · European Journal of Neurology · doi:10.1111/ene.13905 · Cited by 43

Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon‐like peptide‐1 receptor agonists

Yassine, H. N., Solomon, V. A., Thakral, A., Sheikh‐Bahaei, N., Chui, H. C., Braskie, M. N., Schneider, L. S. S., & Talbot, K. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12474 · Cited by 42

Etanercept, an inhibitor of TNF‐a, prevents propofol‐induced neurotoxicity in the developing brain

Chen, B., Deng, X., Wang, B., & Liu, H. (2016) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2016.10.002 · Cited by 41

Neuroinflammation in Friedreich’s Ataxia

Apolloni, S., Milani, M., & D’Ambrosi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116297 · Cited by 40

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats

DellaValle, B., Brix, G. S., Brock, B., Gejl, M., Landau, A. M., Møller, A., Rungby, J., & Larsen, A. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00433 · Cited by 39

Association between diabetes mellitus and risk of Parkinson's disease: A prisma‐compliant meta‐analysis

Liu, W., & Tang, J. (2021) · Brain and Behavior · doi:10.1002/brb3.2082 · Cited by 39

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Bak, A. M., Egefjord, L., Gejl, M., Steffensen, C., Stecher, C. W., Smidt, K., Brock, B., & Rungby, J. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.600691 · Cited by 37

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders

Jung, Y. J., Tweedie, D., Scerba, M. T., Kim, D. S., Palmas, M. F., Pisanu, A., Carta, A. R., & Greig, N. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656921 · Cited by 37

Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients

Pontiroli, A. E., Calderara, A., Perfetti, M. G., & Bareggi, S. R. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315314 · Cited by 36

Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors

Darbalaei, S., Yuliantie, E., Dai, A., Chang, R., Zhao, P., Yang, D., Wang, M.-W., Sexton, P. M., & Wootten, D. L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114150 · Cited by 35

Sustained Release GLP‑1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease

Wang, V., Kuo, T., Huang, E. Y., Ma, K., Chou, Y., Fu, Z.-Y., Lai, L.-W., Jung, J. H., Choi, H.-I., Choi, D., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00013 · Cited by 35

A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer’s Disease1

Cai, H.-Y., Yang, D., Qiao, J., Yang, J.-T., Wang, Z.-J., Wu, M.-N., Qi, J.-S., & Hölscher, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210256 · Cited by 35

Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine

Hoffer, B. J., Pick, C. G., Hoffer, M. E., Becker, R. E., Chiang, Y. H., & Greig, N. H. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0377-1 · Cited by 35

Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury

Bader, M., Li, Y., Lecca, D., Rubovitch, V., Tweedie, D., Glotfelty, E. J., Rachmany, L., Kim, H. K., Choi, H., Hoffer, B. J., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.023 · Cited by 34

3,6’-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation

Lin, C.-T., Lecca, D., Yang, L.-Y., Luo, W., Scerba, M., Tweedie, D., Huang, P.-S., Jung, Y., Kim, D. S., Yang, C.-H., et al. (2020) · eLife · doi:10.7554/elife.54726 · Cited by 34

A novel long‐acting glucose‐dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents

Tatarkiewicz, K., Hargrove, D. M., Jodka, C. M., Gedulin, B. R., Smith, P. A., Hoyt, J. A., Lwin, A. N., Collins, L., Мамедова, Л. Т., Levy, O. E., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12181 · Cited by 33

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 32

Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer's Disease

Qin, L., Chong, T., Rodriguez, R., & Pugazhenthi, S. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160401114751 · Cited by 32

Aging and high-fat diet feeding lead to peripheral insulin resistance and sex-dependent changes in brain of mouse model of tau pathology THY-Tau22

Kacířová, M., Železná, B., Blažková, M., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02190-3 · Cited by 32

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 ( DPP ‐4) inhibitor omarigliptin or the once‐daily DPP ‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy

Goldenberg, R., Gantz, I., Andryuk, P. J., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12832 · Cited by 30

Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury

Li, Y., Glotfelty, E. J., Namdar, I., Tweedie, D., Olson, L., Hoffer, B. J., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113113 · Cited by 29

Microglial Activation of GLP-1R Signaling in Neuropathic Pain Promotes Gene Expression Adaption Involved in Inflammatory Responses

Ma, L., Ju, P., Wang, W., Wei, J., Wang, W., Zhao, M., Ahmad, K. A., Wang, Y., & Chen, J. (2021) · Neural Plasticity · doi:10.1155/2021/9923537 · Cited by 29

GLP-1R Agonist Exendin-4 Protects Against Hemorrhagic Transformation Induced by rtPA After Ischemic Stroke via the Wnt/β-Catenin Signaling Pathway

Liu, C., Sun, S., Xie, J., Li, H., Li, T., Wu, Q., Zhang, Y., Bai, X., Wang, J., Wang, X., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02811-9 · Cited by 28

Liraglutide attenuates the migration of retinal pericytes induced by advanced glycation end products

Lin, W., Ma, X., Hao, M., Zhou, H., Yu, X., Shao, N., Gao, X., & Kuang, H. (2018) · Peptides · doi:10.1016/j.peptides.2018.05.003 · Cited by 27

GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes

Bailey, J., Coucha, M. M., Bolduc, D. R., Burnett, F. N., Barrett, A. C., Ghaly, M., & Abdelsaid, M. A. (2022) · Diabetologia · doi:10.1007/s00125-022-05730-5 · Cited by 27

Waist circumference and risk of Parkinson’s disease

Park, K., Nam, G. E., Han, K., Park, H.-K., & Hwang, H. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00353-4 · Cited by 27

The role of GLP-1/GIP receptor agonists in Alzheimer’s disease

Yu, C. J., Song, L. L., Zhai, Z. N., Tao, Y., Zhang, Y., Cai, L. Y., Hou, Y. H., Chen, H. Y., & Wang, L. (2020) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/121007 · Cited by 23

The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications

Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22

N ‑Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge

Hsueh, S., Luo, W., Tweedie, D., Kim, D. S., Kim, Y. K., Hwang, I., Gil, J.-E., Han, B., Chiang, Y. H., Selman, W. R., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00042 · Cited by 22

Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders

Verma, M. K., Goel, R. N., Nandakumar, K., & Nemmani, K. V. S. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1487952 · Cited by 21

A novel DPP ‐4 inhibitor Gramcyclin A attenuates cognitive deficits in APP / PS1 /tau triple transgenic mice via enhancing brain GLP ‐1‐dependent glucose uptake

Li, Z., Zhang, Y., Meng, X., Li, M., Cao, W., Yang, J., Xu, X., Liu, W., Li, W., Cai, Q., et al. (2022) · Phytotherapy Research · doi:10.1002/ptr.7387 · Cited by 21

3,6′-Dithiopomalidomide Ameliorates Hippocampal Neurodegeneration, Microgliosis and Astrogliosis and Improves Cognitive Behaviors in Rats with a Moderate Traumatic Brain Injury

Huang, P.-S., Tsai, P.-Y., Yang, L., Lecca, D., Luo, W., Kim, D. S., Hoffer, B. J., Chiang, Y. H., Greig, N. H., & Wang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158276 · Cited by 20

PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease

Yu, S., Chen, S., Yang, Y.-Y., Glotfelty, E. J., Jung, Y. J., Kim, H.-K., Choi, H.-I., Choi, D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00785 · Cited by 19

The role of neuroinflammation in the pathogenesis of glaucoma neurodegeneration

Pinazo-Duran, M. D., Muñoz-Negrete, F. J., Sanz-Gonzalez, S. M., Sánchez, J. B. D. C., Giménez-Gómez, R., Valero-Velló, M., Zanón‐Moreno, V., & García‐Medina, J. J. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.07.004 · Cited by 19

Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer’s Disease: Co-Factor Role of Apolipoprotein E ɛ 4

Robbins, J., Busquets, O., Tong, M., & de la Monte, S. M. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200238 · Cited by 19

Pomalidomide Reduces Ischemic Brain Injury in Rodents

Tsai, Y.-R., Tweedie, D., Navas‐Enamorado, I., Scerba, M. T., Chang, C.-F., Lai, J.-H., Wu, J. C.-C., Chen, Y., Kang, S.-J., Hoffer, B. J., et al. (2019) · Cell Transplantation · doi:10.1177/0963689719850078 · Cited by 17

GLP-1/GIP/glucagon receptor triagonism gets its try in humans

Finan, B., & Douros, J. D. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.010 · Cited by 17

An incretin-based tri-agonist promotes superior insulin secretion from murine pancreatic islets via PLC activation

Khajavi, N., Finan, B., Kluth, O., Müller, T. D., Mergler, S., Schulz, A., Kleinau, G., Scheerer, P., Schürmann, A., Gudermann, T. W., et al. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.07.006 · Cited by 16

Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models

KIM, J. A., LEE, S., LEE, S. H., JUNG, S. Y., KIM, Y. H., CHOI, I. Y., & KIM, S. J. (2018) · Diabetes · doi:10.2337/db18-1107-p · Cited by 14

Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Femminella, G. D., Frangou, E., Love, S., et al. (2020) · Trials · doi:10.1186/s13063-020-04608-4 · Cited by 13

Insulin resistance and related factors in patients with moderate and severe traumatic brain injury

Korkmaz, N., Kesikburun, S., Atar, M. Ö., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03147-y · Cited by 13

Insulin-associated neuroinflammatory pathways as therapeutic targets for traumatic brain injury

Cerecedo-Lopez, C. D., Kim-Lee, J. H., Hernandez, D., Acosta, S. A., & Borlongan, C. V. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.11.028 · Cited by 12

Cerebrospinal Fluid Proteomics in Friedreich Ataxia Reveals Markers of Neurodegeneration and Neuroinflammation

Imbault, V., Dionisi, C., Naeije, G., Communi, D., & Pandolfo, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.885313 · Cited by 12

[GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].

Jiao, J., Hölscher, C., Li, T., et al. (2017) · PubMed · Cited by 7

Effects of the Novel Dual GLP-1R/GCGR Agonist SAR425899 on Postprandial Glucose Metabolism in Overweight/Obese Subjects with Type 2 Diabetes

Göbel, B., Schiavon, M., VISENTIN, R., Riz, M., Man, C. D., Cobelli, C., & Klabunde, T. (2018) · Diabetes · doi:10.2337/db18-72-or · Cited by 6

Commentary: The role of inflammation in idiopathic intracranial hypertension

Sudhakar, P. P. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_252_21 · Cited by 5

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193

Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation

Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304

The expanding incretin universe: from basic biology to clinical translation

Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02808-3 · Cited by 181

Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances

Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165

Role of trigger receptor 2 expressed on myeloid cells in neuroinflammation－neglected multidimensional regulation of microglia

Zhang, X., Chen, X., Zhang, L., Sun, Y., Liang, Y., Li, H., & Zhang, Y. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105639 · Cited by 23

Limonin (LM) and its derivatives: Unveiling the neuroprotective and anti-inflammatory potential of LM and V-A-4 in the management of Alzheimer's disease and Parkinson's disease

Panda, S. P., Kesharwani, A., Singh, M., Kumar, S., Mayank, Mallick, S. P., & Guru, A. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.106173 · Cited by 17

TREM2 expression on the microglia resolved lead exposure-induced neuroinflammation by promoting anti-inflammatory activities

Su, P., Zhang, J., Wu, J., Chen, H., Luo, W., & Hu, M. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115058 · Cited by 13

Microglial TREM2 Mitigates Inflammatory Responses and Neuronal Apoptosis in Angiotensin II-Induced Hypertension in Middle-Aged Mice

Xu, X., Du, L., Jiang, J., Yang, M., Wang, Z., Wang, Y., Tang, T., Fu, X., & Hao, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.716917 · Cited by 25

Continuous injection of high-dose lipopolysaccharide modulates microglia polarization via TREM2 to alter the status of septic micePreprint

Qiu, Z., Wang, H., Qu, M., Zhu, S., Zhang, H., Liao, Q., & Miao, C. (2022) · Research Square · doi:10.21203/rs.3.rs-2064325/v1